boehringer ingelheim glp-1 and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight Boehringer Ingelheim brings early data
Description
Takahashi, I., Matsuzaki, T., Kuroki, H
Final thoughts from a mental health perspective Compared to 2023, the conversation around GLP-1s is more grounded and more complex
(2025, April 25)
Tagawa A, Yasuda M, Kume S, Yamahara K, Nakazawa J, Chin-Kanasaki M, et al
Again, the most notable observation was a much lower incidence of hypoglycemia in patients taking the GLP-1R agonist
